Search results
Results from the WOW.Com Content Network
By Leroy Leo. (Reuters) - Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving ...
Guardant Health’s Shield tests could be the first approved blood screening test for colorectal cancer that meets requirements for Medicare reimbursement. Blood test to detect colon cancer could ...
On July 29, 2024, the Food and Drug Administration (FDA) approved a blood test that can help with primary colorectal cancer screening. The test is Guardant Health’s Shield blood test, and the ...
Shield can help improve colorectal cancer screening rates so we can detect more cancers at an early stage, when they are treatable," AmirAli Talasaz, Guardant Health co-CEO, said in a press release.
The company's U.S. initial public offering in 2018 raised $237.5 million, [9] [10] valuing Guardant Health at $3.3 billion. [11] In December 2022, Guardant Health announced the results of a study on its blood-based screening test for colorectal cancers, which it began in 2019.
Since January 2007, the US Medicare program reimburses for colorectal cancer screening with gFOBT only when this code is used. [36] The stool guaiac test method may be preferable to fecal immunochemical testing (FIT) if there is a clinical concern about possible gastric or proximal upper intestinal bleeding. [37]
Veterinary medicine. In veterinary medicine rectal examination is useful in dogs for analysis of the prostate (as in men), pelvic urethra, sublumbar lymph nodes, and anal glands. In horses it is a vital component of the clinical examination for colic, to determine the presence or absence of bowel torsion, impaction, or displacement.
In the U.S., screening is recommended for healthy adults ages 45 to 75 at average risk for colon cancer. Frequency depends on the test: a routine colonoscopy is every 10 years.